Altimmune (NASDAQ:ALT) is a clinical-stage biopharmaceutical company focused on developing treatments that address critical needs in respiratory diseases and immune-modulating therapies. Their operations span the discovery, development, and commercialization of novel products to improve the lives of patients suffering from a range of conditions including obesity, liver diseases, and COVID-19. One of their flagship projects is a vaccine aimed at providing long-lasting protection against influenza, showcasing their commitment to tackling global health challenges. With a strategic approach to innovation and a dedicated team, Altimmune aims to advance its pipeline of promising candidates through the clinical stages, continually seeking to expand its impact on public health worldwide.